Cargando…

A myeloid tumor suppressor role for NOL3

Despite the identification of several oncogenic driver mutations leading to constitutive JAK–STAT activation, the cellular and molecular biology of myeloproliferative neoplasms (MPN) remains incompletely understood. Recent discoveries have identified underlying disease-modifying molecular aberration...

Descripción completa

Detalles Bibliográficos
Autores principales: Stanley, Robert F., Piszczatowski, Richard T., Bartholdy, Boris, Mitchell, Kelly, McKimpson, Wendy M., Narayanagari, Swathi, Walter, Dagmar, Todorova, Tihomira I., Hirsch, Cassandra, Makishima, Hideki, Will, Britta, McMahon, Christine, Gritsman, Kira, Maciejewski, Jaroslaw P., Kitsis, Richard N., Steidl, Ulrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5339683/
https://www.ncbi.nlm.nih.gov/pubmed/28232469
http://dx.doi.org/10.1084/jem.20162089
_version_ 1782512705833271296
author Stanley, Robert F.
Piszczatowski, Richard T.
Bartholdy, Boris
Mitchell, Kelly
McKimpson, Wendy M.
Narayanagari, Swathi
Walter, Dagmar
Todorova, Tihomira I.
Hirsch, Cassandra
Makishima, Hideki
Will, Britta
McMahon, Christine
Gritsman, Kira
Maciejewski, Jaroslaw P.
Kitsis, Richard N.
Steidl, Ulrich
author_facet Stanley, Robert F.
Piszczatowski, Richard T.
Bartholdy, Boris
Mitchell, Kelly
McKimpson, Wendy M.
Narayanagari, Swathi
Walter, Dagmar
Todorova, Tihomira I.
Hirsch, Cassandra
Makishima, Hideki
Will, Britta
McMahon, Christine
Gritsman, Kira
Maciejewski, Jaroslaw P.
Kitsis, Richard N.
Steidl, Ulrich
author_sort Stanley, Robert F.
collection PubMed
description Despite the identification of several oncogenic driver mutations leading to constitutive JAK–STAT activation, the cellular and molecular biology of myeloproliferative neoplasms (MPN) remains incompletely understood. Recent discoveries have identified underlying disease-modifying molecular aberrations contributing to disease initiation and progression. Here, we report that deletion of Nol3 (Nucleolar protein 3) in mice leads to an MPN resembling primary myelofibrosis (PMF). Nol3(−/−) MPN mice harbor an expanded Thy1(+)LSK stem cell population exhibiting increased cell cycling and a myelomonocytic differentiation bias. Molecularly, this phenotype is mediated by Nol3(−/−)-induced JAK–STAT activation and downstream activation of cyclin-dependent kinase 6 (Cdk6) and Myc. Nol3(−/−) MPN Thy1(+)LSK cells share significant molecular similarities with primary CD34(+) cells from PMF patients. NOL3 levels are decreased in CD34(+) cells from PMF patients, and the NOL3 locus is deleted in a subset of patients with myeloid malignancies. Our results reveal a novel genetic PMF-like mouse model and identify a tumor suppressor role for NOL3 in the pathogenesis of myeloid malignancies.
format Online
Article
Text
id pubmed-5339683
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-53396832017-09-06 A myeloid tumor suppressor role for NOL3 Stanley, Robert F. Piszczatowski, Richard T. Bartholdy, Boris Mitchell, Kelly McKimpson, Wendy M. Narayanagari, Swathi Walter, Dagmar Todorova, Tihomira I. Hirsch, Cassandra Makishima, Hideki Will, Britta McMahon, Christine Gritsman, Kira Maciejewski, Jaroslaw P. Kitsis, Richard N. Steidl, Ulrich J Exp Med Research Articles Despite the identification of several oncogenic driver mutations leading to constitutive JAK–STAT activation, the cellular and molecular biology of myeloproliferative neoplasms (MPN) remains incompletely understood. Recent discoveries have identified underlying disease-modifying molecular aberrations contributing to disease initiation and progression. Here, we report that deletion of Nol3 (Nucleolar protein 3) in mice leads to an MPN resembling primary myelofibrosis (PMF). Nol3(−/−) MPN mice harbor an expanded Thy1(+)LSK stem cell population exhibiting increased cell cycling and a myelomonocytic differentiation bias. Molecularly, this phenotype is mediated by Nol3(−/−)-induced JAK–STAT activation and downstream activation of cyclin-dependent kinase 6 (Cdk6) and Myc. Nol3(−/−) MPN Thy1(+)LSK cells share significant molecular similarities with primary CD34(+) cells from PMF patients. NOL3 levels are decreased in CD34(+) cells from PMF patients, and the NOL3 locus is deleted in a subset of patients with myeloid malignancies. Our results reveal a novel genetic PMF-like mouse model and identify a tumor suppressor role for NOL3 in the pathogenesis of myeloid malignancies. The Rockefeller University Press 2017-03-06 /pmc/articles/PMC5339683/ /pubmed/28232469 http://dx.doi.org/10.1084/jem.20162089 Text en © 2017 Stanley et al. http://www.rupress.org/terms/https://creativecommons.org/licenses/by-nc-sa/4.0/This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle Research Articles
Stanley, Robert F.
Piszczatowski, Richard T.
Bartholdy, Boris
Mitchell, Kelly
McKimpson, Wendy M.
Narayanagari, Swathi
Walter, Dagmar
Todorova, Tihomira I.
Hirsch, Cassandra
Makishima, Hideki
Will, Britta
McMahon, Christine
Gritsman, Kira
Maciejewski, Jaroslaw P.
Kitsis, Richard N.
Steidl, Ulrich
A myeloid tumor suppressor role for NOL3
title A myeloid tumor suppressor role for NOL3
title_full A myeloid tumor suppressor role for NOL3
title_fullStr A myeloid tumor suppressor role for NOL3
title_full_unstemmed A myeloid tumor suppressor role for NOL3
title_short A myeloid tumor suppressor role for NOL3
title_sort myeloid tumor suppressor role for nol3
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5339683/
https://www.ncbi.nlm.nih.gov/pubmed/28232469
http://dx.doi.org/10.1084/jem.20162089
work_keys_str_mv AT stanleyrobertf amyeloidtumorsuppressorrolefornol3
AT piszczatowskirichardt amyeloidtumorsuppressorrolefornol3
AT bartholdyboris amyeloidtumorsuppressorrolefornol3
AT mitchellkelly amyeloidtumorsuppressorrolefornol3
AT mckimpsonwendym amyeloidtumorsuppressorrolefornol3
AT narayanagariswathi amyeloidtumorsuppressorrolefornol3
AT walterdagmar amyeloidtumorsuppressorrolefornol3
AT todorovatihomirai amyeloidtumorsuppressorrolefornol3
AT hirschcassandra amyeloidtumorsuppressorrolefornol3
AT makishimahideki amyeloidtumorsuppressorrolefornol3
AT willbritta amyeloidtumorsuppressorrolefornol3
AT mcmahonchristine amyeloidtumorsuppressorrolefornol3
AT gritsmankira amyeloidtumorsuppressorrolefornol3
AT maciejewskijaroslawp amyeloidtumorsuppressorrolefornol3
AT kitsisrichardn amyeloidtumorsuppressorrolefornol3
AT steidlulrich amyeloidtumorsuppressorrolefornol3
AT stanleyrobertf myeloidtumorsuppressorrolefornol3
AT piszczatowskirichardt myeloidtumorsuppressorrolefornol3
AT bartholdyboris myeloidtumorsuppressorrolefornol3
AT mitchellkelly myeloidtumorsuppressorrolefornol3
AT mckimpsonwendym myeloidtumorsuppressorrolefornol3
AT narayanagariswathi myeloidtumorsuppressorrolefornol3
AT walterdagmar myeloidtumorsuppressorrolefornol3
AT todorovatihomirai myeloidtumorsuppressorrolefornol3
AT hirschcassandra myeloidtumorsuppressorrolefornol3
AT makishimahideki myeloidtumorsuppressorrolefornol3
AT willbritta myeloidtumorsuppressorrolefornol3
AT mcmahonchristine myeloidtumorsuppressorrolefornol3
AT gritsmankira myeloidtumorsuppressorrolefornol3
AT maciejewskijaroslawp myeloidtumorsuppressorrolefornol3
AT kitsisrichardn myeloidtumorsuppressorrolefornol3
AT steidlulrich myeloidtumorsuppressorrolefornol3